			0.14 - 4:5: -4	Client Matter No.	SAR	Sheet 1012			
Foi	rm PTC	)-144	9 Modified	FAK-001	Sella ON 533726 Not Yet Known				
			Publications Cited lets if necessary)	Applicant Rajiv Khanna et al.					
U.S. Department of Commerce Patent and Trademark Office					Filing Date herewith	Group Not Yet Known			
FOREIGN PATENT DOCUMENTS									
Examiner			Document No.	Date	Country	Transla	i		
Initial		ı	,	l.		YES	NO		
//	ZL/	AA	1999/002550 A1	01/1999	WIPO				
/ZL/		AB	1229043 A1	08/2002	EP				
/ZL/		AC	2002-255997	09/2002	JAPAN	X			
/ZL/		AD	2001/094944 A2	12/2001	WIPO				
		CUM	ENTS (Including A	uthor, Title, D	Date, Pertinent Page	es, Etc.)			
/ZL/		AE	LEEN A et al.: "Differential Immunogenicity of Epstein-Barr Virus Latent-Cycle Proteins for Human CD4+ T-Helper 1 Responses"; Journal of Virology, September 2001, p 8649-8659						
	,	AF	THORLEY-LAWSON D A et al.: "Generation of specific cytotoxic T cells with a fragment of the Epstein-Barr virus-encoded p63/latent membrane protein"; Proceedings of the National Academy of Sciences of the USA (1987), 84(15), 5384-8						
		AG	O'SULLIVAN DET AL: "Characterization of the specificity of peptide binding to four DR halotypes"; The Journal of Immunology, Vol. 145, No. 6, September 15 1990, pp1799-1808						
		АН	MEIJ P et al.: "Identification and prevalence of CD8+ T-cell responses directed against Epstein-Barr virus-encoded latent membrane protein 1 and latent membrane protein 2"; International Journal of Cancer, 26 February 2002, 99(1), 93-99						
		Al	KHANNA R et al.: "Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1). Evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes"; European Journal of Immunology (1998), 28(2), 451-458						
	DURAISWAMY J et al: "Ex Vivo Analysis of T-Cell Responses to Epstein-Barr Virus-Encoded Oncogene Latent Membrane Protein 1 Reveals highly Conversed Epitope Sequences in Virus Isolates form Divers Geographic Regions"; Journal of Virology, July 2003, pp7401-7410 Vol 77						y Conversed		
EX	EXAMINER /Zachariah Lucas/ DATE CONSIDERED 09/14/2007								

## JC14 R PCT/PTO 04 MAY 2005

Sheet 2 of 2

Form PTC	D-144	9 Modified	Client Matter No. FAK-001	Selially 533726 Not Yet Known			
List of Pate (Use severa	nt and	Publications Cited by Applicant ets if necessary)	Applicant Rajiv Khanna et al.				
Patent and	Trade	of Commerce mark Office	Filing Date herewith	Group Not Yet Known			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
/ZL/	AK	DURAISWAMY J et al: "Therapeutic LMP1 polyepitope vaccine for EBV-associated Hodgkin disease and nasopharyngeal carcinoma"; Blood, 15 April 2003, 101(8), 3150-3156					
/ZL/	AL KHANNA R et al.: "Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease"; Proceedings of the National Academy of Sciences of the USA (1999), 96(18), 10391-10396    AM   GENPEPT accession no AAA53227; SAMPLE J et al.: "Epstein-Barr virus types 1 and 2 have nearly identical LMP-1 transforming genes"; (& PUBMED 7931160) 1994						
· /ZL/							
EXAMINE	₹	/Zachariah Lucas/ DATE C	<b>NSIDERED</b> 09/14/2007				